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Correlates of Treatment Patterns
Among Youth With Type 2
Diabetes
OBJECTIVE
To describe treatment regimens in youth with type 2 diabetes and examine
associations between regimens, demographic and clinical characteristics, and
glycemic control.
RESEARCH DESIGN AND METHODS
This report includes 474 youth with a clinical diagnosis of type 2 diabetes who
completed a SEARCH for Diabetes in Youth study visit. Diabetes treatment regi-
men was categorized as lifestyle alone, metformin monotherapy, any oral hypo-
glycemic agent (OHA) other than metformin or two or more OHAs, insulin
monotherapy, and insulin plus any OHA(s). Association of treatment with demo-
graphic and clinical characteristics (fasting C-peptide [FCP], diabetes duration, and
self-monitoring of blood glucose [SMBG]), and A1C was assessed by x2 and
ANOVA. Multiple linear regression models were used to evaluate independent
associations of treatment regimens and A1C, adjusting for demographics, diabe-
tes duration, FCP, and SMBG.
RESULTS
Over 50% of participants reported treatment with metformin alone or lifestyle. Of
the autoantibody-negative youth, 40%were on metformin alone, while 33% were
on insulin-containing regimens. Participants on metformin alone had a lower
A1C (7.06 2.0%, 536 22mmol/mol) than those on insulin alone (9.26 2.7%, 776
30 mmol/mol) or insulin plus OHA (8.6 6 2.6%, 70 6 28 mmol/mol) (P < 0.001).
These differences remained signiﬁcant after adjustment (7.5 6 0.3%, 58 6 3
mmol/mol; 9.16 0.4%, 766 4mmol/mol; and 8.66 0.4%, 706 4mmol/mol) (P <
0.001) andweremore striking in those with diabetes for ‡2 years (7.96 2.8, 9.96
2.8, and 9.8 6 2.6%). Over one-half of those on insulin-containing therapies still
experience treatment failure (A1C ‡8%, 64 mmol/mol).
CONCLUSIONS
Approximately half of youth with type 2 diabetes were managed with lifestyle or
metformin alone and had better glycemic control than individuals using other
therapies. Those with longer diabetes duration in particular commonly experi-
enced treatment failures, and more effective management strategies are needed.
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Over the last two decades, type 2
diabetes has emerged as a pediatric
condition. As a result, there are few
randomized controlled trials assessing
the safety and efﬁcacy of various
treatment modalities in youth with type
2 diabetes (1–3). In addition, there is
also a paucity of data on the
management strategies used in clinical
practice, with few data on how these
strategies are associated with clinical
course in youth with type 2 diabetes.
Furthermore, analyses of reports on
treatment of youth with type 2 diabetes
may be complicated by the inclusion of
overweight youth clinically diagnosed
with type 2 diabetes but who actually
have autoimmune diabetes
concomitant with their obesity (4–6).
The latter will result in a study
population with a mixture of type 1
and type 2 diabetes.
Metformin is the only approved oral
pharmacologic agent for the treatment
of type 2 diabetes in the pediatric
population, and there is only a limited
number of evidence-based guidelines
for management of type 2 diabetes in
youth (7). Recently, the Treatment
Options for Type 2 Diabetes in Youth
(TODAY) study (3), a multicenter trial of
youth with type 2 diabetes, examined
the long-term safety and efﬁcacy of
metformin alone or in combination with
either rosiglitazone or intensive lifestyle
modiﬁcation. In the metformin
monotherapy group, only half of the
participants maintained optimal
glycemic control over 3–4 years,
suggesting a more rapid deterioration in
glycemic control in adolescents than in
adults with type 2 diabetes (8–10).
To provide further information about
treatment of youthwith type 2 diabetes,
we analyzed cross-sectional data from
the SEARCH for Diabetes in Youth study
(SEARCH) to describe diabetes
treatment regimens used in a large
cohort of youth 10–20 years old with
provider-diagnosed type 2 diabetes. We
examined whether type of treatment
regimen varied by demographic factors,
as is the case with treatment regimens
for type 1 diabetes (11). We also
assessed whether treatment regimen
was associated with glycemic control
and explored whether this association
varied with diabetes duration. Finally
we tested whether, as in observational
studies of adults with type 2 diabetes,
lifestyle changes and metformin were
associated with lower A1C than other
therapies, including insulin (12,13).
RESEARCH DESIGN AND METHODS
Overview of SEARCH
SEARCH is an ongoing multicenter
observational study that conducts
population-based ascertainment of
youth ,20 years of age newly
diagnosed with diabetes (14). Youth
with diabetes were identiﬁed in
geographically deﬁned populations in
Colorado, Ohio, South Carolina, and
Washington; among managed health
care plan enrollees in Hawaii and
California; and among Indian Health
Service beneﬁciaries in selected
American Indian populations. Cases
were considered valid if diagnosed by a
health care provider. For all validated
cases, core demographic and diagnostic
information, including date of birth, sex,
date of diabetes diagnosis, and clinical
diabetes type, was obtained from
medical records. All youth or their
parents/guardians were asked to
complete a short initial survey. Youth
who completed the initial survey and
whose diabetes was not secondary to
another condition were invited to a
study visit.
Data Collection
Study visits were conducted when
participants were metabolically stable
(no episode of diabetic ketoacidosis
during the previous month). Written
informed consent and assent (when
appropriate) were obtained at the start
of the visit in accordance with the
guidelines established by the local
institutional review boards. Participants
were instructed to fast overnight for at
least 8 h and not to take diabetes
medications the morning of the visit
except for basal insulin administered
by a continuous insulin infusion pump.
Blood was drawn, and a urine sample
was collected. Specimens were
processed locally and shipped within 24
h to the central laboratory (Northwest
Lipid Metabolism and Diabetes
Research Laboratories).
Physical examinations at the study visits
were conducted according to
standardized protocols by trained and
certiﬁed staff members. Height and
weight were measured to the nearest
0.5 cm and 0.1 kg. BMI was calculated as
weight in kilograms divided by the
square of height in meters and
converted to BMI z score using a
standard Centers for Disease Control
and Prevention approach (15). Waist
circumference was measured to the
nearest 0.1 cm following the National
Health and Nutrition Examination
Survey (NHANES) protocol (16).
Information collected at the visit
included current use of medications to
treat diabetes and other conditions,
frequency of self-monitoring of blood
glucose (SMBG), type of health care
provider delivering diabetes care,
household structure (one vs. two
parents), household income, highest
level of parent education, and insurance
status. This was collected from parents
or guardians for participants ,18 years
of age and from the participant
themselves if they were age 18 years or
older. Self-reported race and ethnicity
were collected as part of the initial
survey using the 2000 U.S. Census
questions (17).
Diabetes Treatment Regimens and
SMBG
Diabetes treatment regimen was
categorized as follows: 1) lifestyle alone
(no pharmacologic treatment and/or
diet and exercise, 2) metformin alone,
3) any oral hypoglycemic agent (OHA)
(e.g., sulfonylureas, thiazolidinediones,
acarbose) other than metformin or two
or more OHAs (e.g., metformin plus
acarbose), 4) insulin alone, and 5) insulin
plus any OHA(s), including metformin.
For participants on insulin therapy,
information on frequency, mode of
administration, and type(s) of insulin
was collected. Frequency of SMBG was
self-reported and categorized as testing
less than once a day, one to three
times a day, and four times a day or
more.
Laboratory Analyses
Samples were analyzed for GAD65 and
insulinoma-associated protein-2
diabetes autoantibodies (DAs) using a
standardized assay protocol and a
common serum calibrator developed by
the National Institute of Diabetes and
Digestive and Kidney Diseases (NIDDK)-
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sponsored standardization group.
Results were expressed as NIDDK units
(NIDDKU) per milliliter (18). Fasting
C-peptide (FCP) was measured by a two-
site immunoenzymetric assay (Tosoh
Bioscience, San Francisco, CA). The
assay sensitivity is 0.05 ng/mL. A1C
was measured by a dedicated ion-
exchange high-performance liquid
chromatography instrument (Tosoh).
Selection of the Study Population
Sample selection for inclusion in these
analyses is based on clinical diabetes
type, participation in a baseline study
visit, and availability of a fasting blood
sample. Clinical diabetes type was
deﬁned as the diabetes type assigned by
the health care professional around the
time of diagnosis. This was obtained
from medical records or physician
reports and categorized as type 1
(combining type 1, type 1a, and type
1b), type 2, secondary diabetes, and
other types (such as “hybrid,” maturity-
onset diabetes of the young, other type,
and unknown/missing). Of the 548
youth whose clinically diagnosed type 2
diabetes was prevalent in 2001 or
incident in 2002 through 2005 who
attended a baseline SEARCH visit, we
excluded 74 youth who did not have a
fasting blood sample, which resulted
in a ﬁnal sample size of 474 youth for
these analyses.
Statistical Analyses
Because we were interested in
treatments used by youth with clinically
diagnosed type 2 diabetes, we initially
present data on all SEARCH participants
with a clinical diagnosis of type 2
diabetes in our analytic sample. Then, to
avoid possible effects of immune-
mediated b-cell destruction on speciﬁc
key clinical outcomes, we limit some
analyses to those youth with a clinical
diagnosis of type 2 diabetes who had
negative results for both GAD65 and
insulinoma-associated protein-2 DAs
(n = 428 of the 474 participants with
measured DA).
Statistical analyses were conducted
using SAS (version 9.2; SAS Institute,
Cary, NC) with a type I error rate of 0.05.
Outcome variables with right-skewed
distributions (FCP, A1C) are presented
with P values based on log-transformed
values. Associations between DA status
and demographic and clinical
characteristics were analyzed using x2
statistics and t tests for categorical and
continuous variables, respectively.
Comparisons of treatment regimens
were analyzed using x2 statistics and
one-way ANOVA for categorical and
continuous variables, respectively. We
used multiple linear regression analyses
to evaluate independent associations of
treatment regimens and A1C, adjusting
for age, diabetes duration, race/
ethnicity, household income, and
structure (one- vs. two-parent
household), parental education, study
site, FCP, and frequency of SMBG. All
underlying assumptions for normality
and equal variances in residuals for
linear regression and group variances in
ANOVA were conﬁrmed. Further
analyses explored the association
between A1C/FCP and treatment
regimen across subgroups by diabetes
duration (,2 years vs.$2 years), SMBG
(,1 time daily, 1–3 times daily, $4
times daily), and sex. All analyses are
adjusted for age and sex, with the
exception of the sex-subgroup model,
which was adjusted for diabetes
duration. We used logistic regression to
model the odds of A1C $8% vs. ,8%
across treatment and duration
subgroups, adjusted for age and sex, to
allow comparisons with the TODAY
study, where treatment failure was
deﬁned as A1C $8%.
RESULTS
The study sample was comprised of 474
youth with a clinical diagnosis of type 2
diabetes with a mean (SD) duration of
24.2 (22.3) months and a mean age of
16.3 (2.8) years at the study visit. The
majority (63%) were female and from
minority racial and ethnic groups (35%
black, 24% Hispanic, 10% Native
American, and 9% Asian/Paciﬁc
Islander). A majority (64%) reported a
family income of ,50,000 USD (16%
missing data), and over half (61%)
received their diabetes care from a
pediatric endocrinologist. Mean BMI z
score was 1.96 (0.79).
Comparison of DA-Negative and DA-
Positive Participants
Of the total sample, 46 (9.7%) were
positive for at least one of the two DAs
measured by the study. Sex, race/
ethnicity, socioeconomic indices,
diabetes duration, and A1C at the study
visit were not signiﬁcantly different
between DA-negative and DA-positive
participants (data not shown). However,
mean FCP levels were signiﬁcantly
higher (3.6 ng/mL vs. 2.7 ng/mL, P ,
0.0001) in DA-negative participants.
Treatment regimens were signiﬁcantly
different by DA status (P, 0.0001) with
insulin use less common in DA-negative
participants than DA-positive
participants (33 vs. 70%). Management
was lifestyle only in 12.7% of DA-
negative vs. 8.7% of DA-positive and
metformin only medication in 38.2% of
DA-negative vs. 17.4% of DA-positive
participants. Frequency of SMBG
differed signiﬁcantly (P = 0.003) by DA
status, with DA-positive participants
performing SMBG more frequently
(45.5%$4 times daily, 40.9% 1–3 times
daily, and 13.6% more than once daily)
compared with DA-negative
participants (53% 1–3 times daily and
23.2% more than once daily).
Analyses Restricted to DA-Negative
Participants
Demographic, clinical, and laboratory
characteristics of the 428 DA-negative
participants by diabetes treatment
regimen are shown in Table 1.
Metformin monotherapy was the most
common (40%) treatment; however, a
substantial proportion of youth (33%)
were on regimens that included insulin.
The distribution of treatment regimens
differed signiﬁcantly by race/ethnicity
(P = 0.001), although the use of
metformin monotherapy was not
signiﬁcantly different among non-
Hispanic whites, blacks, and Hispanics
(P = 0.25). Treatment regimens also
varied by their type of diabetes care
provider, with participants whose
primary diabetes care provider was a
pediatric endocrinologist most likely to
be on metformin monotherapy (44%).
There were signiﬁcant differences in
A1C by treatment regimen. Participants
on lifestyle and metformin
monotherapy had lower A1C than all
other groups (P , 0.001). These
differences remained signiﬁcant after
adjustment for age, duration, race/
ethnicity, sex, socioeconomic measures
(parental education, household income,
and composition), BMI z score, FCP, and
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frequency of SMBG. When adjusted for
these covariates, A1C was 6.8% for
lifestyle alone, which was signiﬁcantly
lower (P , 0.001) than all other groups
except metformin monotherapy (A1C
7.5%, P = 0.10). The adjusted mean A1C
was signiﬁcantly higher in those treated
with insulin monotherapy than in those
treatedwith lifestyle alone (9.1 vs. 6.8%)
(P, 0.001) or metformin monotherapy
(7.5%, P = 0.003) but it was not
signiﬁcantly different for the other
regimens.When regimenswere combined
to compare those on insulin-containing
regimens and those who were not on
insulin, participants on non–insulin-
containing regimens had a lower A1C
than those on insulin (7.4 vs. 8.8%, P ,
0.001; data not shown). Adjustment for
diabetes duration, FCP, and
demographic and socioeconomic
measures did not change the signiﬁcant
A1C differences by regimen (Table 2).
Frequency of SMBG and Glycemic
Control
Frequency of SMBG varied by treatment
regimen and was associated with A1C.
Participants who reported being treated
with lifestyle or on metformin
monotherapy reported testing less
frequently than those on more intense
regimens (Table 2); 45% of participants
on insulin-containing treatment
regimens reported testing four or more
times, while 64% of participants on
metformin monotherapy tested one to
three times daily and 52% of
participants on lifestyle tested less than
once a day.
Increased frequency of SMBG was
associated with lower A1C in those on
insulin-containing regimens, with mean
A1C signiﬁcantly lower in participants
on insulin who reported testing four or
more times daily compared with those
who tested less frequently (P = 0.01). In
Table 1—Demographic and social characteristics of youth with type 2 diabetes who were DA negative (n = 428) by diabetes
treatment regimen: SEARCH, 2001–2005
Total
(N = 428) Lifestyle
Metformin
only Insulin only
Other OHA**/multiple
OHAs***
Insulin
and OHA P†
N (%) 56 (13.1) 173 (40.4) 48 (11.2) 59 (13.8) 92 (21.5)
Age at in-person visit (years) 16.25 (2.8) 17.4 (2.6) 15.7 (2.5) 16.1 (3.3) 17.6 (2.7) 16.0 (2.3) ,0.001
Female sex, N (%) 272 (63.6) 37 (13.6) 107 (39.3) 32 (11.8) 36 (13.2) 60 (22.1) 0.93
Diabetes duration (months) 24.6 (22.5) 23.6 (22.9) 20.1 (18.0) 32.0 (30.4) 32.5 (23.6) 24.6 (22.3) ,0.001
Race/ethnicity, N (%) ,0.001
Asian/Paciﬁc Islander 39 (9.1) 11 (28.2) 14 (35.9) 5 (12.8) 5 (12.8) 4 (10.3)
Non-Hispanic black 154 (36.0) 12 (7.8) 59 (38.3) 17 (11.0) 16 (10.4) 50 (32.5)
Hispanic 105 (24.5) 18 (17.1) 44 (41.9) 14 (13.3) 15 (14.3) 14 (13.3)
Native American 44 (10.3) 7 (15.9) 13 (29.6) 2 (4.6) 17 (38.6) 5 (11.4)
Non-Hispanic white 83 (19.4) 8 (9.6) 41 (49.4) 10 (12.1) 6 (7.2) 18 (21.7)
Household income (USD), N (%) 0.28
,25,000 173 (40.7) 15 (8.7) 73 (42.2) 24 (13.9) 22 (12.7) 39 (22.5)
25,000–49,000 103 (24.2) 17 (16.5) 40 (38.8) 8 (7.8) 13 (12.6) 25 (24.3)
$50,000 80 (18.8) 15 (18.8) 34 (42.5) 6 (7.5) 10 (12.5) 15 (18.8)
Parental education, N (%) 0.46
,High school graduate 65 (15.6) 9 (13.9) 20 (30.8) 11 (16.9) 9 (13.9) 16 (24.6)
High school graduate 147 (35.3) 14 (9.5) 62 (42.2) 18 (12.2) 21 (14.3) 32 (21.8)
Some college through associate
degree
135 (32.4) 20 (14.8) 62 (45.9) 9 (6.7) 20 (14.8) 24 (17.8)
Bachelor’s degree or more 70 (16.8) 10 (14.3) 26 (37.1) 9 (12.9) 7 (10.0) 18 (25.7)
Household composition, N (%) 0.52
Single parent 199 (46.8) 21 (10.6) 84 (42.2) 24 (12.1) 22 (11.1) 48 (24.1)
Two parents 181 (42.6) 28 (15.5) 72 (39.8) 20 (11.1) 26 (14.4) 35 (19.3)
Other 45 (10.6) 6 (13.3) 17 (37.8) 4 (8.9) 10 (22.2) 8 (17.8)
Health insurance, N (%) ,0.001
Private 216 (51.2) 29 (13.4) 90 (41.7) 24 (11.1) 25 (11.6) 48 (22.2)
Medicaid/Medicare 162 (38.4) 13 (8.0) 74 (45.7) 20 (12.4) 18 (11.1) 37 (22.8)
None/other 44 (10.5) 12 (27.3) 9 (20.5) 4 (9.1) 15 (34.1) 4 (9.1)
Provider type, N (%) ,0.001
Pediatric endocrinologist 260 (61.3) 30 (11.5) 114 (43.9) 27 (10.4) 28 (10.8) 61 (23.5)
Adult endocrinologist 26 (6.1) 4 (15.4) 11 (42.3) 5 (19.2) 2 (7.7) 4 (15.4)
Generalist 67 (15.8) 11 (16.4) 24 (35.8) 4 (6.0) 18 (26.9) 10 (14.9)
Nurse practitioner/physician
assistant
35 (8.3) 2 (5.7) 13 (37.1) 7 (20) 0 (0.0) 13 (37.1)
Other/none 36 (8.5) 8 (22.2) 11 (30.6) 5 (13.9) 10 (27.8) 2 (5.6)
Data are means (SD) unless otherwise indicated. **OHA = yes to any of the following: sulfonylureas (n = 39), thiazolidinedione (n = 18), acarbose
(n = 0), other (n = 6). In the other OHA/multiple OHAs category, 23 participants were taking a single OHA only (not metformin) and 36 reported
multiple OHAs. ***Multiple OHAs = two or more OHAs of metformin, sulfonylureas, thiazolidinedione, acarbose, or other. †P value for association
between the variable and the 5 treatment groups. Comparisons of continuous outcomes, ANOVA; comparisons of categorical outcomes, x2 tests.
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participants on non–insulin-containing
regimens, although A1C trended lower
in those who tested four or more times
daily, this was not signiﬁcant (P = 0.06)
(data not shown).
A1C and FCP Stratiﬁed by Duration of
Diabetes and Insulin Use
Additional model-adjusted analyses
were conducted exploring the
associations between measured A1C
and FCP and treatment regimen across
subgroups based on diabetes duration
(,2 years and $2 years), SMBG
frequency, and sex (Table 3). Overall,
participants with duration of diabetes
$2 years (n = 156, 36%) had signiﬁcantly
higher mean A1C (8.5 vs. 7.8%, P = 0.03)
and signiﬁcantly lowermean FCP (2.8 vs.
3.8 ng/mL, P , 0.001) compared with
participants with shorter diabetes
duration of diabetes (n = 272, 64%)
(Table 3). A1C was signiﬁcantly lower
in participants who were on non–
insulin-containing regimens compared
with those on insulin regardless of
duration (Table 3). All models in Table 3
were adjusted by age and sex except for
sex comparisons, which were adjusted
by age and duration.
We analyzed A1C as a continuous
variable (Table 3) as well as a categorical
variable (Table 4). In unadjusted
analysis, a duration of diabetes.2 years
was associated with a signiﬁcantly
higher frequency of an A1C .8% for
those on metformin monotherapy (14.7
vs. 39.2% with duration ,2 vs. $2
years, P , 0.001) and for those on
insulin plus an OHA (42.4 vs. 73.7% with
duration ,2 years vs. $ 2years, P =
0.009). For those with diabetes duration
$2 years, participants using lifestyle
alone (21.4%) or metformin alone
(39.2%) were less likely to have an A1C
$8% compared with those on more
intensive regimens.
Odds ratios (ORs) were calculated to
determine the likelihood of having an
A1C$8% (whichwe deﬁne as treatment
failure) comparing participants with
diabetes duration $2 years with those
with duration ,2 years. The OR for
having an A1C$8%were also compared
across treatment groups using
metformin alone as the reference
group. Among those with a duration$2
years, the OR was 2.18 (95% CI 1.32–
3.60) for an A1C $8% compared with
the reference group of those with
duration ,2 years. Among the
participants with a duration ,2 years,
all groups had a greater OR of having an
A1C $8% (OR 1.45 – 6.86) compared
with those on metformin alone,
although lifestyle alone was not
statistically signiﬁcantly different. In
those with a duration $2 years, those
on lifestyle alone had a nonsigniﬁcant
OR ,1 of having an A1C $8% (0.27)
compared with those on metformin
alone, while all other groups
continued to have a greater OR of an
A1C$8% (OR 2.45–3.88). As expected,
those on insulin-containing regimens
had a higher OR of treatment
failure (A1C $8%) than those on non–
insulin treatment regimens in both
the duration categories of ,2 years
and $2 years (3.53 and 3.23,
respectively).
For participants with duration of
diabetes ,2 years, mean FCP was not
signiﬁcantly different between those
not on insulin compared with those
using insulin (4.2 ng/mL vs. 3.7 ng/mL,
P = 0.13). However, for those with
duration of diabetes $2 years, mean
FCP was signiﬁcantly lower in
participants who were on insulin
compared with those who were not (2.0
ng/mL vs. 3. 2 ng/mL, P = ,0.001).
A1C and FCP Stratiﬁed by Sex
A1C was different across treatment
regimens for both females and males,
but these results did not differ by sex
(Table 3). Likewise, the A1C for females
and males was different for those on
Table 2—Predictors and effects of treatment modality of youth with type 2 diabetes who were DA negative (n = 428) by
diabetes treatment regimen: SEARCH, 2001–2005
Total (N = 428) Lifestyle Metformin only Insulin only
Other OHA**/
multiple OHAs*** Insulin and OHA P†
A1C ,0.001
% 7.9 (2.5) 7.0 (2.3) 7.0 (2.0) 9.2 (2.7) 9.0 (2.7) 8.6 (2.6)
mmol/mol 63 (27) 53 (25) 53 (22) 77 (30) 75 (30) 70 (28)
A1C adjusted for duration, FCP,
and socioeconomic
variables, mean (SE)^
,0.001
% 8.3 (0.24) 6.8 (0.4) 7.5 (0.3) 9.1 (0.4) 9.0 (0.4) 8.6 (0.4)
mmol/mol 67 (3) 51 (4) 58 (3) 76 (4) 75 (4) 70 (4)
FCP (ng/mL) 3.6 (2.1) 3.9 (2.1) 3.9 (2.1) 2.4 (1.8) 3.4 (2.1) 3.3 (2.3) ,0.001
Fasting serum glucose (mg/dL) 160.5 (80.9) 138.4 (77.6) 138.8 (60.8) 188.0 (89.1) 195.5 (100.1) 182.1 (85.0) ,0.001
Frequency of SMBG, N (%) ,0.001
,Once a day 91 (24.3) 21 (23.1) 39 (42.9) 7 (7.7) 18 (19.8) 6 (6.6)
1–3 times daily 200 (53.3) 15 (7.5) 98 (49.0) 16 (8.0) 27 (13.5) 44 (22.0)
$4 times daily 84 (22.4) 4 (4.8) 15 (17.9) 24 (28.6) 5 (6) 36 (42.9)
Insulin dose (units/kg/day) 0.60 (0.46) d d 0.52 (0.28) 0.57 (0.43) 0.47
Data are means (SD) unless otherwise indicated. **OHA = yes to any of the following: sulfonylureas (n = 39), thiazolidinedione (n = 18), acarbose
(n = 0), other (n = 6). In the other OHA/multiple OHAs category, 23 participants were taking a single OHA only (not metformin) and 36 reported
multiple OHAs. ***Multiple OHAs = two or more OHAs of metformin, sulfonylureas, thiazolidinedione, acarbose, or other. †P value for association
between the variable and the 5 treatment groups. Comparisons of continuous outcomes, ANOVA; comparisons of categorical outcomes, x2 tests.
^Socioeconomic variables include age at initial patient visit, health insurance status, sex, parental education, household income, and household
composition.
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non–insulin-containing regimens and
insulin-containing regimens, but the
mean A1C did not differ by sex.
Females had signiﬁcantly different
treatment regimens across FCP levels,
and those on insulin-containing
regimens had lower mean FCP than
those who were not on insulin (P =
0.002) (Table 3). Males did not have
different regimens based on FCP (P =
0.10). In comparing FCP in females to
males, there was no signiﬁcant
difference within treatment groups or
between those on non–insulin-
containing regimens versus insulin-
containing regimens (P = 0.34 and 0.19,
respectively, for noninsulin vs. insulin-
containing regimens).
CONCLUSIONS
In this SEARCH cohort of youth with DA-
negative type 2 diabetes, treatment
regimens at the time of their study visit
were associated with the participants’
race/ethnicity and clinical factors
including glycemic control, FCP, and
diabetes care provider. Metformin and
lifestyle were the most commonly used
regimens (50% when combined) and
were generally associated with better
glycemic control, regardless of diabetes
duration. Other/multiple OHAs and/or
insulin were more commonly used by
those with higher A1C levels,
particularly among youth with longer
diabetes duration. Regardless of
diabetes duration, youth who were not
on insulin (67% of participants) had
lower A1C than those who were on
insulin (33% of participants). Most
likely, youth on more intensive
regimens, e.g., insulin or multiple
agents, had already failed less intensive
regimens. However, the cross-sectional
design of this observational study does
not allow us to conﬁrm this assumption.
Of great concern is that .50% of these
youth with type 2 diabetes had an A1C
$8% only 2 years after diabetes
diagnosis. While the mean A1C of those
treated with lifestyle alone or on
metformin monotherapy was,8%, less
than half of the participants were on
only these regimens after diabetes
duration of $2 years; in each of the
other regimen groups, mean A1C was
.9%. The percent of youth with an A1C
$8% at 2 years’ duration (55.8%) in the
SEARCH study was higher than that
observed in the TODAY study, where
A1C$8% was observed in 52% of youth
on metformin alone, 39% on metformin
plus rosiglitazone, and 47% on
metformin plus lifestyle 3–4 years after
being diagnosed with diabetes. This
difference is most likely due to the
selective entry criteria for the TODAY
trial as well as to the increased attention
provided to participants in the TODAY
study treatment trial compared with
participants in SEARCH, an
observational study.
As expected, longer duration of diabetes
was associated with lower FCP in youth
on insulin-containing regimens, a
reﬂection of declining endogenous
insulin secretion. Participants treated
with lifestyle alone or on metformin
monotherapy had lower A1C values and
higher FCP, and these differences in A1C
remained after adjusting for multiple
covariates including demographics, FCP,
BMI, frequency of SMBG, and duration
of diabetes. The higher OR for
experiencing treatment failure (A1C
$8%) in those on more intensive
regimens most likely reﬂects a decline in
FCP noted in these youth and points out
the need for additional effective therapy
for adolescents and young adults with
type 2 diabetes as endogenous insulin
secretion wanes.
Current recommendations for SMBG in
youth with type 2 diabetes are not
evidence based. Among youth with DA-
negative type 2 diabetes treated with
insulin in our study, we observed that
increased frequency of SMBG was
signiﬁcantly associated with lower A1C,
while no association was observed
among youth who were on regimens
that did not include insulin. There is
controversy over the effect of SMBG on
glycemic control in adults with type 2
diabetes, with a recent meta-analysis
showing that more frequent SMBG was
not associated with lower A1C (19).
However, our results emphasize the
importance of SMBG among youth with
type 2 diabetes treated with insulin
showing that SMBG is an important
correlate of A1C. Additional data are
needed on the efﬁcacy of SBGM for
improving glycemia in youth with T2D
according to treatment regimen.
Approximately 10% of youth in this
report with clinically diagnosed type 2
diabetes were positive for at least one of
the two DA measured in this study.
These youthwere similar to DA-negative
youth in terms of their A1C,
demographic, and many clinical
characteristics but had lower FCP andwere
more likely to be on insulin-containing
regimens. This is consistent with other
reports, including youth with clinically
diagnosed type 2 diabetes screened for
Table 4—ORs (95% CI) of A1C$8.0% (64 mmol/mol)† among youth with type 2 diabetes by treatment regimen and duration of
diabetes: SEARCH, 2001–2005
Total
(N 5 428)
Noninsulin therapy Insulin therapy
Lifestyle
(n 5 56)
Metformin only
(n 5 173)
Other OHA/
multiple OHAs
(n 5 59)
Insulin only
(n 5 48)
Insulin and
metformin/insulin and
other OHA (n 5 92)
DM duration
,2 years
1.00 (–) 1.45 (0.60–3.54) 1.00 (–) 4.85 (1.84–12.81) 6.86 (2.68–17.60) 4.45 (2.14–9.23)
1.00 (–) 3.53 (1.56–6.68)
DM duration
$2 years
2.18 (1.32–3.60) 0.27 (0.06–1.12) 1.00 (–) 2.45 (0.98–6.14) 3.55 (1.16–10.89) 3.88 (1.48–10.19)
1.00 (–) 3.23 (1.99–6.24)
†ORs for A1C$8% are organized as follows: overall duration$2 years vs. duration,2 years (reference), within-duration category odds of each of 4
treatments (lifestyle, other OHA/multiple OHAs, insulin only, insulin plus metformin/OHA) vs. metformin only (reference), and odds of insulin vs.
noninsulin (reference).
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potential participation in the TODAY study
(6). As we have described in an earlier
SEARCH publication on etiological
classiﬁcation of diabetes in youth, DA-
positive youth with clinically diagnosed
type 2 diabetes likely represent obese
youth with autoimmune diabetes (4).
There are several limitations that should
be considered when interpreting the
ﬁndings of our study. We are unable to
take into consideration the treatment
decisions made by the health care
providers treating these youth, the
study participants, or their parents that
may have inﬂuenced the selection of
their regimens. Similarly, we do not
know the timing of the initiation of the
regimens in relation to the timing of the
study visit, when the blood was
collected for A1C measurement. The
information on how regimens were
selected or timing of initiation was not
collected as part of the study protocol.
Because these analyses are cross-
sectional and timing of regimen
initiation is unknown, causal
relationships between regimens and
A1C cannot be inferred. Similarly, we are
not able to assess adherence to the
prescribed pharmacological regimens or
lifestyle efforts to treat type 2 diabetes
or health care and diabetes education
received by these youth. Finally, data on
treatment regimen and SMBG are self-
reported. However, the strengths of this
report include the relatively large size
and multiracial and ethnic composition
of the cohort of youth with type 2
diabetes and the consistency of data
collection using a common protocol
across the six centers and over time.
These results are based on the
treatment regimens of youth with type
2 diabetes diagnosed through 2005 who
were seen from 2002 through 2007d
a relatively contemporary cohort. As
newer therapies, such as glucagon-like
peptide-1 agonists, are introduced into
clinical therapies in the care of youth, it
will be of great interest to follow this
cohort and further assess changes in
regimens and outcomes.
Over half of the youth with type 2
diabetes with a duration of $2 years
had an A1C $8%, representing a failure
of their diabetes treatment, despite
almost 60% being on more “intensive”
management regimens; .50% of those
on intensive regimens still experience
treatment failures. These data indicate
that current management strategies are
not resulting in adequate glycemic
control in these youth. More effective
therapies and/or therapeutic strategies
are needed for youth with type 2
diabetes that will lead to better
glycemic control and thus lower risk of
diabetes complications as adults.
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